Adlai Nortye Ltd. Sponsored ADR (ANL) – What Are Brokerages Saying About This Stock?

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) have been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $29.50.

Several equities research analysts have recently weighed in on the stock. Loop Capital set a $49.00 target price on shares of Adlai Nortye in a research note on Tuesday, September 8th. Wall Street Zen upgraded Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a research report on Tuesday, September 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday, October 12th. Finally, Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th.

Insider Buying and Selling

In other news, CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $13.98, for a total value of $83,880.00. Following the transaction, the chief financial officer owned 153,424 shares of the company’s stock, valued at approximately $2,144,867.52. The trade was a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the sale, the director directly owned 121,453 shares of the company’s stock, valued at approximately $1,942,033.47. This represents a 7.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 26,881 shares of company stock worth $411,060.

Institutional Trading of Adlai Nortye

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC increased its stake in shares of Adlai Nortye by 8.5% during the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after acquiring an additional 1,279 shares during the period. Renaissance Technologies LLC purchased a new position in Adlai Nortye during the first quarter worth about $457,000. Seven Fleet Capital Management LP acquired a new stake in Adlai Nortye in the second quarter valued at about $1,302,000. ADAR1 Capital Management LLC acquired a new stake in Adlai Nortye in the first quarter valued at about $816,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Adlai Nortye in the first quarter valued at about $1,140,000. Hedge funds and other institutional investors own 35.21% of the company’s stock.

Adlai Nortye Stock Performance

NASDAQ ANL opened at $10.58 on Friday. The firm’s fifty day moving average is $14.20 and its two-hundred day moving average is $12.82. Adlai Nortye has a one year low of $0.88 and a one year high of $17.25.

Adlai Nortye Company Profile

Adlai Nortye (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research is centered on treatments designed to stimulate or enhance the immune system’s ability to identify and attack cancer cells.

Adlai Nortye’s pipeline includes buparlisib, an oral pan-class I phosphoinositide 3-kinase inhibitor being investigated in oncology. The company has evaluated buparlisib in combination with immunotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.